Detalles de la búsqueda
1.
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).
Br J Cancer
; 130(2): 224-232, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37973958
2.
Reply to L. Celio et al.
Br J Cancer
; 130(12): 1887-1888, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38750116
3.
Current Status and Issues of Collaboration Between Physicians and Pharmacists in Fertility Preservation.
J Adolesc Young Adult Oncol
; 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38569162
4.
Antiemetic Efficacy of Adding Olanzapine 5 mg to Aprepitant, Palonosetron and Dexamethasone-Sparing After Day Two for Cancer Patients Receiving Anthracycline and Cyclophosphamide.
Cancer Manag Res
; 13: 1617-1624, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33628052
5.
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy.
BMJ Open
; 10(12): e041737, 2020 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33334838
6.
Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy.
J Clin Oncol
; 36(10): 1000-1006, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29443652
Resultados
1 -
6
de 6
1
Próxima >
>>